Effect of Immune Thrombocytopenic Purpura Medications on Depression Risk: An Analysis of NHANES Data
Annals of Pharmacotherapy · 2025
DOI: 10.1177/10600280241267930 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Pharmacotherapy, 2025. Verfasst von Feiyue Zheng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, China. Hauptthemen laut MEDLINE: Purpura, Thrombocytopenic, Idiopathic, Depression. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: zhejiang pharmaceutical association, natural science foundation of zhejiang province.
Themen: Depression
Abstract (Originalsprache)
Background
Immune thrombocytopenic purpura (ITP) in adults typically develops slowly and insidiously. The ITP medications might be linked to psychological disorders, but the connection is not well-understood.
Objective
This study aimed to examine the association between ITP medication use and the risk of depression among participants in the National Health and Nutrition Examination Survey (NHANES) from 2005 to 2018.
Methods
Using data from 70 190 NHANES participants, we conducted a cross-sectional study, excluding individuals under 18 years, with hypertension, HIV, hepatitis C, and various comorbidities. A total of 17 299 individuals were included in the analysis of this study. We identified 2 populations within this study: those using ITP medications, including prednisone, dexamethasone, and rituximab and those not using ITP drugs. Depression status was assessed using the Patient Health Questionnaire–9 (PHQ-9), and the relationship between ITP medication use and depression was analyzed through multivariate logistic regression.
Results
There was no significant association between ITP medication use and an increased risk of depression after adjusting for demographic and health-related variables. Notably, among the study participants, 1.8% of the non-depressed population were on ITP medication compared with 0.3% in the depressed population. The analysis revealed varying depression risks associated with different sociodemographic factors. For instance, the correlation between ITP medication and depression risk was influenced by a combination of age, race, income, and smoking status. Conclusion and Relevance: The study suggests that ITP medication use does not independently increase the risk of depression. This finding is crucial for guiding clinical decisions and managing patient expectations regarding ITP treatment and its psychological impacts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
- The Yangtze River Delta Biological Medicine Research and Development Center of Zhejiang Province, Yangtze Delta Region Institution of Tsinghua University, Hangzhou, China.
- Department of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
ORCID-Profile: Jiaying Wu, Yuefeng Rao
Förderung
- zhejiang pharmaceutical association
- natural science foundation of zhejiang province
Zitieren
APA
Zheng, F., Yu, Z., Zhang, Z., Miao, J., Wang, W., Wu, J., & Rao, Y. (2025). Effect of Immune Thrombocytopenic Purpura Medications on Depression Risk: An Analysis of NHANES Data. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280241267930
Vancouver
Zheng F, Yu Z, Zhang Z, Miao J, Wang W, Wu J, et al. Effect of Immune Thrombocytopenic Purpura Medications on Depression Risk: An Analysis of NHANES Data. Annals of Pharmacotherapy. 2025. doi:10.1177/10600280241267930
BibTeX
@article{Zheng2025,
author = {Zheng, Feiyue and Yu, Zhengwei and Zhang, Zhang and Miao, Jinli and Wang, Wenmin and Wu, Jiaying and Rao, Yuefeng},
title = {Effect of Immune Thrombocytopenic Purpura Medications on Depression Risk: An Analysis of NHANES Data},
journal = {Annals of Pharmacotherapy},
year = {2025},
doi = {10.1177/10600280241267930}
}
EUVIMED